Medicine and Health

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

X. Leleu, C. Hulin, et al.

This groundbreaking phase 3 study reveals that isatuximab combined with bortezomib significantly enhances minimal residual disease negativity and complete response rates in older multiple myeloma patients. Conducted by leading experts including Xavier Leleu and Philippe Moreau, the findings suggest a potential new standard of care in this challenging demographic.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study

F. Saj, Y. Nisha, et al.

Medicine and Health

The effects of omega 3 fatty acids on the serum concentrations of pro inflammatory cytokines and depression status in patients with bipolar disorder: A randomized double-blind controlled clinical trial

H. Eslahi, M. Shakiba, et al.

Medicine and Health

Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial

M. V. D. Heiden, S. Shetty, et al.

Medicine and Health

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 Neo Trio trial

G. V. Long, M. S. Carlino, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny